HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/1/H183    most recent 00490.2002v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Hasan, A. A. K. Articles by Schmaier, A. H. Search for Related Content PubMed PubMed Citation Articles by Hasan, A. A. K. Articles by Schmaier, A. H.

Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin

¹Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0640; ²Thromgen, Incorporated, Ann Arbor 48104; and ³Department of Chemistry, Michigan State University, East Lansing, Michigan 48824

Submitted 11 June 2002 ; accepted in final form 3 February 2003

Investigations determined the mechanism(s) by which Arg-Pro-Pro-Gly-Phe (RPPGF) inhibits thrombin-induced platelet activation. High concentrations of RPPGF inhibit thrombin-induced coagulant activity. RPPGF binds to the active site of thrombin by forming a parallel -strand with Ser²¹⁴-Gly²¹⁶ and interacts with His⁵⁷, Asp¹⁸⁹, and Ser¹⁹⁵ of the catalytic triad. RPPGF competitively inhibits -thrombin from hydrolyzing Sar-Pro-Arg-paranitroanilide with a K_i = 1.75 ± 0.03 mM. Other mechanisms were sought to explain why RPPGF inhibits thrombin activation of platelets at concentrations below that which inhibits its active site. Soluble RPPGF blocks biotinylated NATLDPRSFLLR of the thrombin cleavage site on protease-activated receptor (PAR)1 from binding to the peptide RPPGC (IC₅₀ = 20 µM). The soluble recombinant extracellular domain of PAR1 (rPAR1_EC) blocks biotinylated RPPGF binding to rPAR1_EC (IC₅₀ = 50 µM) bound to microtiter plates, but rPAR1_EC deletion mutants missing the sequence LDPR or PRSF do not. RPPGF and related forms prevent the thrombin-like enzyme thrombocytin from proteolyzing rPAR1_EC at concentrations that do not block thrombocytin's active site. These studies indicate that RPPGF is a bifunctional inhibitor of thrombin: it binds to PAR1 to prevent thrombin cleavage at Arg⁴¹ and interacts with the active site of -thrombin.

protease-activated receptor 1; bradykinin-(1–5); thrombin inhibitor; thrombin receptor

This article has been cited by other articles:

				A. M. Marney, J. Ma, J. M. Luther, T. A. Ikizler, and N. J. Brown Endogenous Bradykinin Contributes to Increased Plasminogen Activator Inhibitor 1 Antigen following Hemodialysis J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2246 - 2252. [Abstract] [Full Text] [PDF]

				Z. Shariat-Madar, F. Mahdi, M. Warnock, J. W. Homeister, S. Srikanth, Y. Krijanovski, L. J. Murphey, A. A. Jaffa, and A. H. Schmaier Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin Blood, July 1, 2006; 108(1): 192 - 199. [Abstract] [Full Text] [PDF]

				R. Zamorano, S. Suchindran, and J. V. Gainer 3'-Untranslated region of the type 2 bradykinin receptor is a potent regulator of gene expression Am J Physiol Renal Physiol, February 1, 2006; 290(2): F456 - F464. [Abstract] [Full Text] [PDF]

				Z. Shariat-Madar, F. Mahdi, and A. H. Schmaier Recombinant prolylcarboxypeptidase activates plasma prekallikrein Blood, June 15, 2004; 103(12): 4554 - 4561. [Abstract] [Full Text] [PDF]